Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study

Overview

Journal Inflamm Bowel Dis

Publisher Oxford University Press

Specialty Gastroenterology

Date 2018 Jan 24

PMID 29361097

Citations 6

Authors

Aaron Yarlas

Geert DHaens

Mary Kaye Willian

Megan Teynor

Affiliations

Soon will be listed here.

Abstract

Background: Disease activity of patients with ulcerative colitis (UC) predicts health-related quality of life (HRQL) and work-related outcomes (eg, absenteeism, productivity). We tested whether outcomes differed among patients in complete (clinical and endoscopic) remission, partial remission, or not in remission following treatment with multimatrix mesalamine.

Methods: Data were from an open-label, multicountry, prospective trial (ClinicalTrials.gov identifier: NCT01124149) of 717 adults with active mild-to-moderate UC treated with 4.8 g/day multimatrix mesalamine tablets for 8 weeks (induction period); 459 patients who achieved partial or complete remission received daily 2.4 g/day multimatrix mesalamine for 12 additional months (maintenance period). HRQL (SF-12v2 Health Survey and Short Inflammatory Bowel Disease Questionnaire) and work-related outcomes (Work Productivity and Activity Impairment questionnaire) were assessed at baseline and final visits of each treatment period. Differences in scores by remission status within each treatment period were tested using analysis of variance and analysis of covariance models, whereas mixed-effects models with repeated measures tested changes over time.

Results: At their final visit of each treatment period, patients in partial remission scored significantly better on all HRQL and work-related domains than patients not in remission (all Bonferroni-adjusted P < 0.05). Scores for patients in partial remission were, almost without exception, statistically equivalent to those for patients in complete remission. Fluctuating between complete and partial remission during maintenance treatment had no impact on outcomes.

Conclusions: Patients in partial remission following multimatrix mesalamine treatment had HRQL and work-related outcomes equivalent to patients in complete remission. Achievement and maintenance of partial remission may be sufficient for improvements in patients' functioning, well-being, and work performance.

Citing Articles

Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study.

Alarfaj S, Bahaa M, Elmasry T, Elberri E, El-Khateeb E, Hamouda A Drug Des Devel Ther. 2024; 18:5239-5253.

PMID: 39575188 PMC: 11578921. DOI: 10.2147/DDDT.S490772.

Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial.

Alrubaiy L, Hutchings H, Louca A, Rapport F, Watkins A, Sebastian S J Pers Med. 2022; 12(12).

PMID: 36556259 PMC: 9784102. DOI: 10.3390/jpm12122039.

The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.

Yarlas A, Willian M, Nag A Qual Life Res. 2021; 30(7):1925-1938.

PMID: 33651279 PMC: 8233235. DOI: 10.1007/s11136-021-02787-4.

Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial.

Nagahori M, Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T Digestion. 2021; 102(5):742-752.

PMID: 33454706 PMC: 8491515. DOI: 10.1159/000512235.

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results.

Teich N, Grummer H, Jorgensen E, Liceni T, Holtkamp-Endemann F, Fischer T World J Gastroenterol. 2020; 26(21):2852-2863.

PMID: 32550760 PMC: 7284175. DOI: 10.3748/wjg.v26.i21.2852.

References

Reilly M, Zbrozek A, Dukes E . The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993; 4(5):353-65. DOI: 10.2165/00019053-199304050-00006. View

Hjortswang H, Jarnerot G, Curman B, Sandberg-Gertzen H, Tysk C, Blomberg B . Validation of the inflammatory bowel disease questionnaire in Swedish patients with ulcerative colitis. Scand J Gastroenterol. 2001; 36(1):77-85. DOI: 10.1080/00365520150218093. View

Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada J . Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol. 2001; 13(5):567-72. DOI: 10.1097/00042737-200105000-00017. View

Pallis A, Vlachonikolis I, Mouzas I . Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece. BMC Gastroenterol. 2002; 2:1. PMC: 65681. DOI: 10.1186/1471-230x-2-1. View

Hjortswang H, Jarnerot G, Curman B, Sandberg-Gertzen H, Tysk C, Blomberg B . The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis. Eur J Gastroenterol Hepatol. 2003; 15(9):1011-20. DOI: 10.1097/00042737-200309000-00012. View

Casellas F, Alcala M, Prieto L, Miro J, Malagelada J . Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol. 2004; 99(3):457-61. DOI: 10.1111/j.1572-0241.2004.04071.x. View

Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M . Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004; 53(12):1813-6. PMC: 1774334. DOI: 10.1136/gut.2003.038505. View

Higgins P, Schwartz M, Mapili J, Zimmermann E . Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?. Am J Gastroenterol. 2005; 100(2):355-61. DOI: 10.1111/j.1572-0241.2005.40641.x. View

Casellas F, Arenas J, Baudet J, Fabregas S, Garcia N, Gelabert J . Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005; 11(5):488-96. DOI: 10.1097/01.mib.0000159661.55028.56. View

10.

Kane S . Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006; 23(5):577-85. DOI: 10.1111/j.1365-2036.2006.02809.x. View

11.

Kamm M, Sandborn W, Gassull M, Schreiber S, Jackowski L, Butler T . Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007; 132(1):66-75. DOI: 10.1053/j.gastro.2006.10.011. View

12.

DHaens G, Sandborn W, Feagan B, Geboes K, Hanauer S, Irvine E . A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132(2):763-86. DOI: 10.1053/j.gastro.2006.12.038. View

13.

Hawthorne G, Osborne R, Taylor A, Sansoni J . The SF36 Version 2: critical analyses of population weights, scoring algorithms and population norms. Qual Life Res. 2007; 16(4):661-73. DOI: 10.1007/s11136-006-9154-4. View

14.

Ren W, Lai M, Chen Y, Irvine E, Zhou Y . Validation of the mainland Chinese version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2007; 13(7):903-10. DOI: 10.1002/ibd.20128. View

15.

Rutgeerts P, Vermeire S, Van Assche G . Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut. 2007; 56(4):453-5. PMC: 1856849. DOI: 10.1136/gut.2005.088732. View

16.

Reinisch W, Sandborn W, Bala M, Yan S, Feagan B, Rutgeerts P . Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis. 2007; 13(9):1135-40. DOI: 10.1002/ibd.20165. View

17.

Cooney R, Warren B, Altman D, Abreu M, Travis S . Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials. 2007; 8:17. PMC: 1919394. DOI: 10.1186/1745-6215-8-17. View

18.

Froslie K, Jahnsen J, Moum B, Vatn M . Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133(2):412-22. DOI: 10.1053/j.gastro.2007.05.051. View

19.

Lewis J, Chuai S, Nessel L, Lichtenstein G, Aberra F, Ellenberg J . Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008; 14(12):1660-6. PMC: 2597552. DOI: 10.1002/ibd.20520. View

20.

Lichtenstein G, Rutgeerts P . Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009; 16(2):338-46. DOI: 10.1002/ibd.20997. View